Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
On behalf of World Courier and Arena International, we wish to cordially invite all attendees at the upcoming Outsourcing in Clinical Trials Nordic Conference to a first evening drinks reception to be held immediately following the conclusion of Day 1 activities.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Testimonials from other events in our Outsourcing in Clinical Trials Series
Immunovaccine has received Health Canada clearance to conduct a Phase II clinical trial of its lead cancer vaccine candidate, DPX-Survivac, to treat patients with diffuse large B cell lymphoma (DLBCL).
Galena Biopharma has completed patient enrolment in the GALE-401, or Anagrelide Controlled Release, Phase II clinical trial to treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET…
US-based biopharmaceutical firm Novavax has started patient enrolment in a Phase II clinical trial of its recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate (Seasonal Influenza VLP).
US-based biopharmaceutical firm Sarepta Therapeutics has dosed the first patient in a clinical trial of its lead exon-skipping therapeutic candidate eteplirsen to treat Duchenne muscular dystrophy (DMD).
US-based biotechnology firm Five Prime Therapeutics has started dosing in its Phase I clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), to treat patients with rheumatoid arthritis (RA).
Bristol-Myers Squibb has reported positive results from a Phase III trial (CheckMate -066) comparing an investigational PD-1 immune checkpoint inhibitor, Opdivo, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type a…